An Evaluation Of The Prescription Pattern Of IDegAsp And Its Clinical Outcomes In Indian Clinical Practice
The study was presented from Jothydev’s Diabetes Research Center, Trivandrum at the International Diabetes
Federation Congress 2019, organized by IDF at Busan. The Research team headed by Dr.Jothydev Kesavadev
included Dr.Banshi Saboo, Dr.Shashank R Joshi, Dr.Arun Shankar, Dr. Ashwin David Ashok, Lakshmy Ramachandran
and Sunitha Jothydev.
IDegAsp, the first soluble co-formulation which contains 70% basal IDeg and 30% mealtime IAsp, has a
unique pharmacodynamic profile. Postprandial and fasting hyperglycemia can be effectively controlled,
without increasingthe hypoglycaemia risk. IDeg component provides a stable basal insulin action over a
24-h period whereas the IAsp component bestows prandial control, which is unaffected by the basal
This study is a retrospective evaluation of the prescription pattern and the clinical outcomes of
IDegAsp among T2DM subjects in a real-world setting of Indian clinical practice. Clinical characteristics
and demographics of T2DM subjects prescribed with IDegAsp and on regular follow-up were captured from
our EMRs. There were 291 participants with mean age of 53.59 ± 11.80 years, and T2DM duration of 11.05
± 6.28 years. About 74.14% of the study participants were males. IDegAsp treatment duration as on 1st
April 2018 was 10.51 ± 8.53 months. Previous treatment regimen of the patients were OHA only, n= 87;
OHA + insulin, n=176; OHA + insulin + GLP1RA, n=7 [3 patients discontinued GLP1RA upon IDegAsp
initiation], and treatment naive [started on IDegAsp + OHAs, n=17; started on IDegAsp+OHAs+GLP1RA,
IDegAsp treatment resulted in significant improvement in the clinical profiles. Overall reduction from
baseline: FBS- 34.93 mg/dl, p<0.0001; PPBS- 65.09, p<0.0001; HbA1c- 1.470, p<0.0001. Changes in body
weight, BMI and TDD of insulin were non-significant. Negligible number of hypoglycaemic episodes
reported (0.007 events/person, non severe, no nocturnal hypos). Initially, 32.88% and 67.12% of the
subjects were on IDegAsp once daily (q.d) and twice daily (b.i.d) respectively. Later, 22.92 % of the
subjects in the q.d regimen had to be intensified to b.i.d and 3.57% of the subjects in the b.i.d were
shifted to q.d.
In this real-world study of Indian clinical practice, prescription data indicated that the IDegAsp
co-formulation is effective across a range of clinical profiles including treatment naive subjects.
It significantly improved clinical outcomes, with negligible hypoglycaemia and no weight gain. To a
great extent, IDegAsp could thus help eliminate the concerns regarding insulin intensifications and
achieve clinical outcomes in a large proportion of T2DM individuals.